5311462025-04-012025-06-305311462025-06-305311462025-04-012025-06-30in-capmkt:OtherExpenses1Member5311462025-06-30Statement15311462025-04-012025-06-30Statement15311462025-06-30StatementDynamic1I1Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares531146MEDICAMEQNOTLISTEDINE646B01010MEDICAMEN BIOTECH LIMITEDMain BoardEquity2025-04-012026-03-312025-08-122025-08-07INRLakhsQuarterlyFirst quarterSingle segmentPharmaceuticals2025-08-1212:00:002025-08-1215:30:00Not applicabletrue1true2025-04-012025-06-30UnauditedStandalone38449000047030003891930002387780000-188490005305300056220001773000071165000367499000216940000216940005695000-3680005327000016367000000016367000016367000135628000101.211.21001.211.21Other Expenses711650002549370000000Preferential Issues2025-04-245356810002025-06-30falsefalseNAThere is no deviation/variation in the utilization of fundsNAParul ChoudharyCompany Secretary and Compliance OfficerNew Delhi2025-08-12The Company intends to utilize the proceeds raised through the issue of Equity Shares and Fully Convertible Warrants (“Issue Proceeds”) towards the following objects: a) Drug Development of 50 SKUs for Regulated markets: The company intends to develop 50 SKUs in oncology, diabetes, and cardiovascular diseases (CVD) for regulated markets such as the US, EU, Canada, and Australia. The development process requires significant investment in: • Procurement of R&D quantities of new molecules. • Formulation development, analytical method validation, and stability studies across different climatic zones. • Execution of engineering and validation batches, including process validation and stability studies. • Import of Reference Listed Drugs (RLDs) and conducting in vitro Comparative Dissolution Profile (CDP) and Bioequivalence (BE) studies, which involve substantial costs. b) Registration of dossiers, etc.: • Preparation and submission of Electronic common technical document (eCTD) which contains all information and documents of product development for product registration in regulated markets, requiring highly skilled personnel and outsourcing of non-clinical data. • Payment of high regulatory fees, which are mandatory at the time of dossier submission. c) Meet the Enhanced working capital requirements: • Augmenting resources for Quality Control (QC) and Quality Assurance (QA) at manufacturing facilities. • Recruitment of experienced international marketing professionals to drive expansion in regulated markets. • Strengthening distribution and sales networks to support market penetration. d) Capital expenditure in some area of upgradation of the existing facilities: In the existing facilities of the Company, Capex is required to be undertaken for additional instruments, packaging machines, and compliance tools to meet country-specific regulatory requirements for new products. e) Expansion of operations in Domestic Market: • Strengthening the company’s footprint in oncology, diabetes, and CVD segments by establishing new regional headquarters across India. • Expansion of the salesforce, including the recruitment of 200+ field representatives and managers. • Increased participation in domestic medical conferences to enhance brand recognition and engagement with healthcare professionals. f) General Corporate PurposesNA53568100001453720000